After almost twenty years of intense medication specific government regulation buprenorphine is now just like other schedule III medications. The era of limited numbers of treatment slots that started at 30 patients per provider who had completed 8 hours of specific training, requirements to maintain lists of patients who received prescriptions and even in person visits by DEA agents to a large percentage of prescribers in the US is over. Our Government can make changes that help patients and providers, but not without the strong advocacy of ASAM and CSAM members like you.
Matthew Torrington, MD, Chair of CSAM's Opioid Committee
|